Matches in SemOpenAlex for { <https://semopenalex.org/work/W2606133764> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2606133764 abstract "e14604 Background: Nimotuzumab is a genetically engineered humanized antibody (mAb) that recognizes an epitope located in the extracellular domain of human EGFR. Evidences have shown that nimotuzumab is effective and safe in SCCHN. The combination of paclitaxel/cisplatin (TP) is a standard regimen for advanced or metastatic ESCC. This open uncontrolled phase II study was designed to determine the efficacy and safety of nimotuzumab in combination with TP as the first-line treatment in advanced ESCC. Methods: All patients have histology/cytology confirmed advanced or metastatic ESCC with ECOG PS 0-2. The treatment plan is as the following: paclitaxel administered intravenously (IV) 175 mg/m2 on d1 and cisplatin IV 30-35mg/ m2/d on d1-2, every 21 days for 6 cycles, and nimotuzumab IV 200mg weekly. For patients with stable disease (SD) and better, nimotuzumab will be given continuously after 6 cycles of TP. The primary endpoint is objective response rate (RR) with 56 patients enrollment (target RR >60%); secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety/ tolerability. The coordinations between EGFR and ERCC1 with response of treatment will be analyzed. Results: Up to date, 25 patients (male/female, 20/5; median age 58) have been enrolled. All patients were evaluated for toxicity and 22 are evaluable for response. 14 (63.6%) had a confirmed partial response (PR) and 7 (31.8%) had SD as their best responses with disease control rate of 95.4%. Only one patient had progressive disease (PD). Grade 3 or 4 neutropenia, neutropenic fever and anemia occurred in 52.2%, 4% and 13% respectively. Nonhematological toxicities were generally mild with grade 1 or 2 alopecie, hypodynamia, anorexia, nausea, arthralgia, and itch of skin occurring in 80%, 60.9%, 43.5%, 34.8%, 30.4%, and 21.7%. One patient had a grade 3 haematuria. Conclusions: The interim analysis showed that the combination of nimotuzumab with TP is tolerated reasonably well in patients with advanced or metastatic ESCC and encouraging efficacy. The study is ongoing with coordination of biomarkers and response as well." @default.
- W2606133764 created "2017-04-28" @default.
- W2606133764 creator A5006511913 @default.
- W2606133764 creator A5034342116 @default.
- W2606133764 creator A5035364200 @default.
- W2606133764 creator A5035535613 @default.
- W2606133764 creator A5035804461 @default.
- W2606133764 creator A5046118596 @default.
- W2606133764 creator A5052883326 @default.
- W2606133764 creator A5054785361 @default.
- W2606133764 creator A5068252474 @default.
- W2606133764 creator A5072537482 @default.
- W2606133764 creator A5073838859 @default.
- W2606133764 creator A5073995543 @default.
- W2606133764 date "2012-05-20" @default.
- W2606133764 modified "2023-09-27" @default.
- W2606133764 title "Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis." @default.
- W2606133764 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e14604" @default.
- W2606133764 hasPublicationYear "2012" @default.
- W2606133764 type Work @default.
- W2606133764 sameAs 2606133764 @default.
- W2606133764 citedByCount "0" @default.
- W2606133764 crossrefType "journal-article" @default.
- W2606133764 hasAuthorship W2606133764A5006511913 @default.
- W2606133764 hasAuthorship W2606133764A5034342116 @default.
- W2606133764 hasAuthorship W2606133764A5035364200 @default.
- W2606133764 hasAuthorship W2606133764A5035535613 @default.
- W2606133764 hasAuthorship W2606133764A5035804461 @default.
- W2606133764 hasAuthorship W2606133764A5046118596 @default.
- W2606133764 hasAuthorship W2606133764A5052883326 @default.
- W2606133764 hasAuthorship W2606133764A5054785361 @default.
- W2606133764 hasAuthorship W2606133764A5068252474 @default.
- W2606133764 hasAuthorship W2606133764A5072537482 @default.
- W2606133764 hasAuthorship W2606133764A5073838859 @default.
- W2606133764 hasAuthorship W2606133764A5073995543 @default.
- W2606133764 hasConcept C121608353 @default.
- W2606133764 hasConcept C126322002 @default.
- W2606133764 hasConcept C143998085 @default.
- W2606133764 hasConcept C166957645 @default.
- W2606133764 hasConcept C2776055544 @default.
- W2606133764 hasConcept C2776694085 @default.
- W2606133764 hasConcept C2776957806 @default.
- W2606133764 hasConcept C2777292972 @default.
- W2606133764 hasConcept C2778239845 @default.
- W2606133764 hasConcept C2779438470 @default.
- W2606133764 hasConcept C2779742542 @default.
- W2606133764 hasConcept C3019814559 @default.
- W2606133764 hasConcept C31760486 @default.
- W2606133764 hasConcept C535046627 @default.
- W2606133764 hasConcept C61943457 @default.
- W2606133764 hasConcept C71924100 @default.
- W2606133764 hasConcept C95457728 @default.
- W2606133764 hasConceptScore W2606133764C121608353 @default.
- W2606133764 hasConceptScore W2606133764C126322002 @default.
- W2606133764 hasConceptScore W2606133764C143998085 @default.
- W2606133764 hasConceptScore W2606133764C166957645 @default.
- W2606133764 hasConceptScore W2606133764C2776055544 @default.
- W2606133764 hasConceptScore W2606133764C2776694085 @default.
- W2606133764 hasConceptScore W2606133764C2776957806 @default.
- W2606133764 hasConceptScore W2606133764C2777292972 @default.
- W2606133764 hasConceptScore W2606133764C2778239845 @default.
- W2606133764 hasConceptScore W2606133764C2779438470 @default.
- W2606133764 hasConceptScore W2606133764C2779742542 @default.
- W2606133764 hasConceptScore W2606133764C3019814559 @default.
- W2606133764 hasConceptScore W2606133764C31760486 @default.
- W2606133764 hasConceptScore W2606133764C535046627 @default.
- W2606133764 hasConceptScore W2606133764C61943457 @default.
- W2606133764 hasConceptScore W2606133764C71924100 @default.
- W2606133764 hasConceptScore W2606133764C95457728 @default.
- W2606133764 hasLocation W26061337641 @default.
- W2606133764 hasOpenAccess W2606133764 @default.
- W2606133764 hasPrimaryLocation W26061337641 @default.
- W2606133764 hasRelatedWork W1988515091 @default.
- W2606133764 hasRelatedWork W2017115004 @default.
- W2606133764 hasRelatedWork W2065254819 @default.
- W2606133764 hasRelatedWork W2168730865 @default.
- W2606133764 hasRelatedWork W2222455017 @default.
- W2606133764 hasRelatedWork W2268972469 @default.
- W2606133764 hasRelatedWork W2281489466 @default.
- W2606133764 hasRelatedWork W2516281563 @default.
- W2606133764 hasRelatedWork W2564982514 @default.
- W2606133764 hasRelatedWork W2789300355 @default.
- W2606133764 hasRelatedWork W2890192392 @default.
- W2606133764 hasRelatedWork W2913137317 @default.
- W2606133764 hasRelatedWork W2965052056 @default.
- W2606133764 hasRelatedWork W2968438182 @default.
- W2606133764 hasRelatedWork W3000171942 @default.
- W2606133764 hasRelatedWork W3031041011 @default.
- W2606133764 hasRelatedWork W3087085123 @default.
- W2606133764 hasRelatedWork W3097088857 @default.
- W2606133764 hasRelatedWork W3124478254 @default.
- W2606133764 hasRelatedWork W3166027474 @default.
- W2606133764 isParatext "false" @default.
- W2606133764 isRetracted "false" @default.
- W2606133764 magId "2606133764" @default.
- W2606133764 workType "article" @default.